Results 51 to 60 of about 75,218 (96)

GLP-1 at the Metabolic-Cognitive Interface: Reward, Affect, and Memory. [PDF]

Compr Physiol
Gao SX, Décarie-Spain L, Gu C, Mazzini G, Kanoski SE, Borner T.   +5 more
europepmc   +1 more source

Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations. [PDF]

Diabetes Metab Syndr Obes
Yılmaz N, Bastemir M.
europepmc   +1 more source

Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy. [PDF]

ACG Case Rep J
Madej J, Gonzaga ER, Naveed M.
europepmc   +1 more source

The promise of GLP-1 receptor agonists for neurodegenerative diseases. [PDF]

J Clin Invest
Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S.   +4 more
europepmc   +1 more source

GLP-1 receptor agonists and conscious sedation. [PDF]

Interv Pain Med
Holder EK, Ni A, Levi D, International Pain and Spine Intervention Society's Patient Safety Committee.   +3 more
europepmc   +1 more source

National Utilization and Expenditure Trends of GLP-1 Receptor Agonists and Dual GLP-1/GIP Agonist in Croatia, 2017-2024. [PDF]

Medicina (Kaunas)
Car M, Erceg D, Udovičić M, Bokun T, Rahelić D.   +4 more
europepmc   +1 more source

The emerging implications of GLP-1 receptor agonists in radiation therapy. [PDF]

Oncologist
Reinicke T, Dilworth JT.
europepmc   +1 more source

Crystallization and 1.6 Å resolution crystal structure of an acylated GLP-1/GIP analogue peptide. [PDF]

Acta Crystallogr F Struct Biol Commun
Mitchell HM, Nocek B, Guinn EJ, Heng JYY.   +3 more
europepmc   +1 more source

Time-Related Biases in Observational Studies of GLP-1 Agonists and Cancer Risk. [PDF]

J Diabetes
Lu F.
europepmc   +1 more source

Med14 phosphorylation shapes genomic response to GLP-1 agonists. [PDF]

Proc Natl Acad Sci U S A
Van de Velde S, Yu J, Garrett Evensen K, Pakhlevanyan E, Williams AE, Shaw RJ, Montminy M.   +6 more
europepmc   +1 more source